GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Devonian Health Group Inc (TSXV:GSD) » Definitions » ROE %

Devonian Health Group (TSXV:GSD) ROE % : 31.10% (As of Jul. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Devonian Health Group ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Devonian Health Group's annualized net income for the quarter that ended in Jul. 2024 was C$4.32 Mil. Devonian Health Group's average Total Stockholders Equity over the quarter that ended in Jul. 2024 was C$13.90 Mil. Therefore, Devonian Health Group's annualized ROE % for the quarter that ended in Jul. 2024 was 31.10%.

The historical rank and industry rank for Devonian Health Group's ROE % or its related term are showing as below:

TSXV:GSD' s ROE % Range Over the Past 10 Years
Min: -124.19   Med: -34.86   Max: -8.53
Current: -8.85

During the past 11 years, Devonian Health Group's highest ROE % was -8.53%. The lowest was -124.19%. And the median was -34.86%.

TSXV:GSD's ROE % is ranked better than
74.41% of 1305 companies
in the Biotechnology industry
Industry Median: -43.68 vs TSXV:GSD: -8.85

Devonian Health Group ROE % Historical Data

The historical data trend for Devonian Health Group's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Devonian Health Group ROE % Chart

Devonian Health Group Annual Data
Trend Jun15 Jun16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -43.17 -39.58 -28.98 -30.14 -8.53

Devonian Health Group Quarterly Data
Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -24.58 -20.43 -35.61 -11.29 31.10

Competitive Comparison of Devonian Health Group's ROE %

For the Biotechnology subindustry, Devonian Health Group's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Devonian Health Group's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Devonian Health Group's ROE % distribution charts can be found below:

* The bar in red indicates where Devonian Health Group's ROE % falls into.



Devonian Health Group ROE % Calculation

Devonian Health Group's annualized ROE % for the fiscal year that ended in Jul. 2024 is calculated as

ROE %=Net Income (A: Jul. 2024 )/( (Total Stockholders Equity (A: Jul. 2023 )+Total Stockholders Equity (A: Jul. 2024 ))/ count )
=-1.225/( (14.247+14.462)/ 2 )
=-1.225/14.3545
=-8.53 %

Devonian Health Group's annualized ROE % for the quarter that ended in Jul. 2024 is calculated as

ROE %=Net Income (Q: Jul. 2024 )/( (Total Stockholders Equity (Q: Apr. 2024 )+Total Stockholders Equity (Q: Jul. 2024 ))/ count )
=4.324/( (13.347+14.462)/ 2 )
=4.324/13.9045
=31.10 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jul. 2024) net income data. ROE % is displayed in the 30-year financial page.


Devonian Health Group  (TSXV:GSD) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jul. 2024 )
=Net Income/Total Stockholders Equity
=4.324/13.9045
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(4.324 / 36.56)*(36.56 / 28.039)*(28.039 / 13.9045)
=Net Margin %*Asset Turnover*Equity Multiplier
=11.83 %*1.3039*2.0165
=ROA %*Equity Multiplier
=15.43 %*2.0165
=31.10 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jul. 2024 )
=Net Income/Total Stockholders Equity
=4.324/13.9045
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (4.324 / 4.324) * (4.324 / 4.84) * (4.84 / 36.56) * (36.56 / 28.039) * (28.039 / 13.9045)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.8934 * 13.24 % * 1.3039 * 2.0165
=31.10 %

Note: The net income data used here is four times the quarterly (Jul. 2024) net income data. The Revenue data used here is four times the quarterly (Jul. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Devonian Health Group ROE % Related Terms

Thank you for viewing the detailed overview of Devonian Health Group's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Devonian Health Group Business Description

Traded in Other Exchanges
Address
360, Rue des Entrepreneurs, Montmagny, QC, CAN, G5V 4T1
Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provides a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. Its product portfolio includes pharmaceuticals like Thykamine, Pantoprazole, and Cleo-35; and cosmeceutical products like R-Spinasome and Purgenesis.

Devonian Health Group Headlines

No Headlines